

FORM PTO-1390 (REV. 11-2000)		U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER GJE-68
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U S APPLICATION NO (If known, see 37 CFR 1.5 09/856944
INTERNATIONAL APPLICATION NO. PCT/GB99/04013	INTERNATIONAL FILING DATE 01 December 1999		PRIORITY DATE CLAIMED 01 December 1998	
TITLE OF INVENTION Isolated Material Having An Anti-Organotrophic Effect				
APPLICANT(S) FOR DO/EO/US John Ernest Hart				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input checked="" type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)), <u>unsigned</u>. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 				
Items 11 to 20 below concern document(s) or information included: <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). <input type="checkbox"/> Other items or information: 				

U.S. APPLICATION NO. If known, see 37 CFR 1.51 09/856944	INTERNATIONAL APPLICATION NO PCT/GB99/04013	ATTORNEY'S DOCKET NUMBER GJE-68																				
<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p>		CALCULATIONS PTO USE ONLY																				
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860.00																				
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p>																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;">\$</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>18 - 20 =</td> <td>0</td> <td>x \$18.00</td> <td>\$0.00</td> </tr> <tr> <td>Independent claims</td> <td>3 - 3 =</td> <td>0</td> <td>x \$80.00</td> <td>\$0.00</td> </tr> <tr> <td colspan="2">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td></td> <td>+ \$270.00</td> <td>\$0.00</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	18 - 20 =	0	x \$18.00	\$0.00	Independent claims	3 - 3 =	0	x \$80.00	\$0.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$0.00	\$860.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																		
Total claims	18 - 20 =	0	x \$18.00	\$0.00																		
Independent claims	3 - 3 =	0	x \$80.00	\$0.00																		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$0.00																		
TOTAL OF ABOVE CALCULATIONS =		\$860.00																				
<p><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.</p>		\$0.00																				
SUBTOTAL =		\$860.00																				
<p>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p>		\$0.00																				
TOTAL NATIONAL FEE =		\$860.00																				
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</p>		\$0.00																				
TOTAL FEES ENCLOSED =		\$860.00																				
<input type="checkbox"/> Amount to be refunded: \$ <input type="checkbox"/> charged: \$																						
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>19-0065</u> in the amount of \$ <u>860.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0065</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>																						
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</p>																						
<p>CORRESPONDENCE ADDRESS:</p> <p>CUSTOMER NUMBER 23,557</p> <p style="text-align: center;"><u>May 30, 2001</u></p> <p style="text-align: center;">DATE</p> <p>SIGNATURE <u>David Saliwanchik</u></p> <p>NAME David R. Saliwanchik</p> <p>31,794</p> <p>REGISTRATION NUMBER</p>																						

May 30, 2001

PRELIMINARY AMENDMENT
Patent Application

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : John Ernest Hart

Docket No. : GJE-68

For : Isolated Material Having An Anti-Organotrophic Effect

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified patent application as follows:

In the Claims

The following amendments are made with respect to the claims in the international application PCT/GB99/04013.

Please amend the following claims to read as follows:

2. The material according to claim 1, wherein the purifying comprises obtaining the 1-30 kD fraction.
3. The material according to claim 1, wherein the purifying comprises obtaining the 10-20 kD fraction.
4. The material according to claim 3, wherein the purifying additionally comprises ion exchange chromatography, and collecting the fraction eluted in 0.1-0.2 M NaCl.

5. The material according to claim 1, wherein the purifying comprises the following protocol:

plasma cleared by centrifugation;
cleared plasma spun to give a nominal 0-30 kD fraction;
nominal 0-30 kD fraction spun to give a nominal 10-30 kD sub-fraction;
nominal 10-30 kD sub-fraction concentrated and gel-filtered to give a nominal 10-20 kD sub-fraction;
nominal 10-20 kD sub-fraction repeatedly concentrated and buffer-diluted, applied to an ion exchange column eluted with a gradient of 0-0.3 M NaCl; and
eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.

6. The material according to claim 1, wherein the mammal is a sheep.

8. A pharmaceutical composition comprising a material having the ability to reduce organ mass, the material being obtainable by:

collecting ovarian venous blood from a female mammal;
preparing ovarian venous plasma from the blood; and
at least partially purifying said material from the plasma
and a pharmaceutically acceptable excipient or carrier.

Please cancel claims 7 and 9 and add the following new claims:

10. The pharmaceutical composition, according to claim 8, wherein the purifying comprises obtaining the 1-30 kD fraction.

11. The pharmaceutical composition, according to claim 8, wherein the purifying comprises obtaining the 10-20 kD fraction.

12. The pharmaceutical composition, according to claim 8, wherein the purifying additionally comprises ion exchange chromatography, and collecting the fraction eluted in 0.1-0.2 M NaCl.

13. The pharmaceutical composition, according to claim 8, wherein the purifying comprises the following protocol:

plasma cleared by centrifugation;
cleared plasma spun to give a nominal 0-30 kD fraction;
nominal 0-30 kD fraction spun to give a nominal 10-30 kD sub-fraction;
nominal 10-30 kD sub-fraction concentrated and gel-filtered to give a nominal 10-20 kD sub-fraction;
nominal 10-20 kD sub-fraction repeatedly concentrated and buffer-diluted, applied to an ion exchange column eluted with a gradient of 0-3 M NaCl; and
eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.

14. The pharmaceutical composition, according to claim 8, wherein the mammal is a sheep.

15. A method for treating organ or tissue hypertrophy wherein said method comprises administering, to a patient in need of such treatment, an effective amount of a material having the ability to reduce organ mass, the material being obtainable by:

collecting ovarian venous blood from a female mammal;
preparing ovarian venous plasma from the blood; and
at least partially purifying said material from the plasma.

16. The method, according to claim 15, wherein the purifying comprises obtaining the 1-30 kD fraction.

17. The method, according to claim 15, wherein the purifying comprises obtaining the 10-20 kD fraction.

18. The method, according to claim 15, wherein the purifying additionally comprises ion exchange chromatography, and collecting the fraction eluted in 0.1-0.2 M NaCl.

19. The method, according to claim 15, wherein the purifying comprises the following protocol:

plasma cleared by centrifugation;

cleared plasma spun to give a nominal 0-30 kD fraction;

nominal 0-30 kD fraction spun to give a nominal 10-30 kD sub-fraction;

nominal 10-30 kD sub-fraction concentrated and gel-filtered to give a nominal 10-20 kD sub-fraction;

nominal 10-20 kD sub-fraction repeatedly concentrated and buffer-diluted, applied to an ion exchange column eluted with a gradient of 0-3 M NaCl; and

eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.

20. The method, according to claim 15, wherein the mammal is a sheep.


Remarks

Claims 1-6 and 8 have been amended, claims 7 and 9 have been canceled, and new claims 10-20 have been added.

No new matter has been added by these amendments.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606

DRS/la

Marked-up Version of amended claims

2. The [A] material according to claim 1, wherein the purifying comprises obtaining the 1-30 kD fraction.

3. The [A] material according to claim 1, wherein the purifying comprises obtaining the 10-20 kD fraction.

4. The [A] material according to claim 3, wherein the purifying additionally comprises ion exchange chromatography, and collecting the fraction eluted in 0.1-0.2 M NaCl.

5. The [A] material according to claim 1, wherein the purifying comprises the following protocol:

plasma cleared by centrifugation;
cleared plasma spun to give a nominal 0-30 kD fraction;
nominal 0-30 kD fraction spun to give a nominal 10-30 kD sub-fraction;
nominal 10-30 kD sub-fraction concentrated and gel-filtered to give a nominal 10-20 kD sub-fraction;
nominal 10-20 kD sub-fraction repeatedly concentrated and buffer-diluted, applied to an ion exchange column eluted with a gradient of 0-3 M NaCl; and
eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.

6. The [A] material according to [any preceding claim] claim 1, wherein the mammal is a sheep.

8. A pharmaceutical composition comprising a material having the ability to reduce
organ mass, the material being obtainable by:

collecting ovarian venous blood from a female mammal;

preparing ovarian venous plasma from the blood; and

at least partially purifying said material from the plasma

[according to any of claims 1 to 6] and a pharmaceutically acceptable excipient or carrier.

ISOLATED MATERIAL HAVING AN ANTI-ORGANOTROPHIC EFFECTField of the Invention

The present invention relates to an isolated material which generally reduces organ mass, and to its therapeutic use.

5 Background of the Invention

The mammalian gonads secrete a variety of hormones, such as oestrogen and testosterone, and other signalling molecules, such as growth factors and cytokines, which have effects throughout the body. Mechanisms regulating the masses of tissues and organs can in their totality be described as the "organotrophic system".

10 The endocrine (hormonal) contribution to this system includes the hypothalamic-pituitary-gonadal axis, the adrenals, the thyroid and other endocrine tissues. Among the generally positive endocrine influences in the organotrophic system are oestrogen and testosterone. Organotrophic effects of oestrogens are discussed by Hart, Pharmac. Ther. (1990) 47:203-218.

15 Hart, Toxicology (1990) 61:185-194, reported that the oestrogen antagonist, clomiphene, could decrease most organ weights in female rats. Hart postulated that clomiphene may act as an antagonist of the known positive organotrophic oestrogen effect.

Summary of the Invention

20 The present invention is based on the discovery of an endogenous material (described herein as "micrin") which can diminish the size and weight of many organs and tissues throughout the body. Micrin can be obtained by a process which comprises:

- 25 (i) treating a female mammal with clomiphene citrate (this step is optional);
- (ii) collecting ovarian venous blood from the mammal;
- (iii) preparing ovarian venous plasma from the blood collected in step (ii); and
- (iv) at least partially purifying micrin from the ovarian venous plasma.

30 Micrin may be defined as an endogenous material which is inducible by clomiphene and has the effect in general of reducing organ or tissue mass in a mammalian body. Micrin may be a single compound or a group of compounds. Micrin has a molecular weight range of nominally 10-20 kD when purified from blood as

defined herein although it is possible that it is a larger or smaller moiety having physico-chemical properties which cause it to behave as if it were a moiety of 10-20 kD. Further, it is possible that the active component is of lower molecular weight through its being associated (covalently, or more likely non-covalently) with a carrier,

5 or by being a fragment of the micrin that has been identified, or that the 10-20 kD moiety is a biologically active fragment of a larger entity.

Without wishing to be bound by theoretical considerations, it is believed that micrin is a newly discovered hormone produced principally by mammalian gonads, although other sources of the hormone are contemplated. This is the first time that

10 a hormone with widespread negative influence on organ size has been discovered. Indeed there existed a technical prejudice in the art, away from the presence invention, which believed there were mainly positive endocrine influences on organ size; organ shrinkage being presumed to be brought about by absence of a positive factor (such as for example pituitary trophic hormones). This invention introduces a

15 novel entity (micrin) which is generally a negative influence on organ size (although individual organs may respond differently).

The mechanism of action of micrin is not yet understood. It may involve one or more of cell shrinkage, inhibition of cell division and an increased effect in apoptosis, or micrin may be associated with a substance having such effects.

20 Brief Description of the Drawings

Figures 1 to 5 each show the results of bioassays, versus controls, of the effect of micrin, at various stages of isolation, on the weights of various organs.

Description of the Invention

With reference to the four-step process defined above, step (iv) preferably

25 comprises obtaining the 10-30 kD molecular weight fraction from ovarian venous plasma, for example by membrane filtration. More preferably, step (iv) comprises obtaining the 10-20 kD molecular weight fraction from ovarian venous plasma, for example by gel filtration chromatography. Most preferably, step (iv) further comprises subjecting the 10-20 kD fraction to further purification by ion exchange


30 chromatography and collecting the fraction eluted in 0.1-0.2 M NaCl. The procedure is fully described in the Examples, below. The following Protocol and Flow Diagram are summaries:

PROTOCOL

1. Plasma cleared by centrifugation at +4°C and 4000 rpm for 5 minutes.

2. Cleared plasma spun through Amicon Centriprep-30 cartridges at 2000 rpm to give a nominal 0-30 kD fraction.
3. Nominal 0-30 kD fraction spun through Amicon Centriprep-10 to give a nominal 10-30 kD sub-fraction.
- 5 4. Nominal 10-30 kD sub-fraction concentrated and gel filtered through a Pharmacia FPLC Superdex-75 column to give a nominal 10-20 kD sub-fraction.
5. Nominal 10-20 kD sub-fraction repeatedly concentrated and buffer diluted and applied to a Pharmacia FPLC Mono-Q ion exchange column eluted with a gradient of 0-0.3 M NaCl. Eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.

FLOW DIAGRAM



If necessary or desired, further, standard purification/fractionation procedures 25 may be conducted. These include physico-chemical methods, such as HPLC, FPLC, gel filtration, electrophoresis, column chromatography, ion exchange chromatography, isoelectric focusing, or using immuno-affinity columns.

The presence of micrin at any stage can be confirmed by the bioassay 30 reported below, as Example 3. Micrin may also exist in other fractions than those obtained by the recited steps, but its effect is generally less in such other fractions.

Micrin-rich plasma may be obtained from a suitable mammal such as a sheep. For example, the sheep (approximately 70 kg) is treated with clomiphene citrate at 1.5 g/day on Day 3 post-oestrus of its reproductive cycle and the following 3 days, as

described herein. Depending on factors such as the age of the sheep, clomiphene induction may be unnecessary.

Preferably, the micrin, e.g. obtained by the given procedure, has a specific activity of at least 1 unit/ml. A unit of micrin is defined as an amount of micrin which when administered daily is sufficient to decrease the relative (post-exsanguination) organ weight of the female rat heart by 5% when administered in 4 equal daily doses using the bioassay described herein.

Micrin has therapeutic utility. In particular, it may be used for the treatment of organ or tissue hypertrophy and/or hyperplasia in a mammal. Specific conditions that may be treated include, for example, cardiac or prostatic hypertrophy, polycystic ovarian syndrome, endometriosis polycystic renal disease and pituitary adenoma.

For this purpose, it may be used in the form obtained by extraction or further purification, as described above, or it may be formulated, as a medicament. Thus, according to another aspect of the present invention, a pharmaceutical composition comprises micrin and a pharmaceutically acceptable excipient or carrier. A preferred pharmaceutical composition is suitable for parenteral administration such as, for example, an injectable solution, preferably sterile. Other suitable non-injectable methods of administration, for which micrin may be formulated as appropriate, are oral and nasal.

Suitable carriers and excipients, and other suitable additives, are known to those skilled in the art. For example, a micrin solution may be prepared in a sterile form using any suitable technique such as for example sterile filtration.

The dosage to be administered can be determined, having regard to typical factors, by one skilled in the art. A suitable dosage is 1-25 ml/day of micrin having a specific activity of about 1 unit/ml. A preferred dosage is 2.5-10 ml/day and especially 5 ml/day.

Micrin may also be used as a research tool for exploring a novel mammalian micrin hormone system and/or the organotrophic system. It may also be used to screen for agonists or antagonists of micrin such as, for example, by mixing a potential agonist or antagonist compound with the partially purified micrin described herein and measuring differences in the bioassay described herein compared with appropriate controls. Micrin may also be used as a surrogate marker in clinical trials, to screen potential drugs for undesirable toxicological properties on the micrin hormonal system

as detectable in the bioassay described herein, and to detect effects on the wider organotrophic system.

The following Examples illustrate the invention, with reference to the accompanying drawings, in which:

5 Figure 1 illustrates a bioassay ($n = 10$) of test ovarian venous plasma from a clomiphene-treated sheep ("active plasma") in the female rat versus a control of jugular venous plasma from an ovariectomised ("ovx") sheep, untreated with clomiphene;

10 Figure 2 illustrates the bioassay ($n = 11$) of a 10-30 kD fraction of active plasma in the female rat versus a control of a 10-30 kD fraction of ovx sheep venous plasma;

15 Figure 3 illustrates the bioassay ($n = 8$) of a 10-20 kD sub-fraction of active plasma in the female rat versus a control ($n = 5$) of a 10-20 kD sub-fraction of ovx sheep venous plasma;

20 Figure 4 illustrates the bioassay ($n = 5$) of a 0.1-0.2 M NaCl ion exchange fraction ("active ion exchange fraction") of the 10-20 kD sub-fraction of active plasma in the female rat versus a control ($n = 20$) of physiological, pyrogen-free saline; and

25 Figure 5 illustrates the bioassay ($n = 5$) of the active ion exchange fraction in the male rat versus a control of a 0.1-0.2 M NaCl ion exchange fraction of the 10-20 kD sub-fraction of ovx sheep venous plasma.

The data in the Figures were obtained thus: the mean relative (post-exsanguination) organ weights of the test rats were first expressed as a percentage of the control means. These figures were then subtracted from 100 to yield the percentage difference between test and control means, the results being plotted 25 against a zero baseline representing control values. The asterisks in the Figures represent the statistical significance, thus:

* = $p < 0.05$, ** = $p < 0.02$, *** = $p < 0.01$, **** = $p < 0.002$, ***** = $p < 0.001$.

The statistical analysis involved Student's *t*-test.

Example 1 Preparation of Micrin

30 1. Isolation of sheep ovarian venous plasma

Multiparous non-pregnant ewes were used. Ewes were housed with a vasectomised ram to detect the day of oestrus (day 0). On day 3, post-oestrus ewes were injected intramuscularly with clomiphene citrate (Sigma Chemical Co., Poole, UK, catalogue no. C6272) at a dose of 1.5 g/day, dissolved in warm physiological,

pyrogen-free saline to a final volume of 10 ml. Clomiphene injections were repeated on days 4, 5 and 6 post-oestrus. On day 6, post-oestrus and under pentobarbitone (RMB Animal Health Ltd., Dagenham, UK) anaesthesia, ovarian venous blood was collected from the sheep, following the method of Heap *et al*, J. Reprod. Fert. (1985)

5 74:645-656, into heparin (1 i.u./ml blood) (C.P. Pharmaceuticals Ltd., Wrexham, UK) to prevent clotting. Blood samples were immediately placed on ice until centrifugation. The ovarian venous plasma was then obtained from the ovarian venous blood by centrifugation at +4°C and 4000 rpm for 20 minutes. The plasma layer was then removed and stored in a plastic bottle in a freezer at -10°C.

10 2. Preparation of the nominal 0-30 kD molecular weight fraction from sheep ovarian plasma

The plasma (from 1 above) was cleared by centrifugation at +4°C and 4000 rpm for 5 minutes. The cleared plasma fraction was then poured into an Amicon Centriprep-30, a centrifuge device with concentric inner and outer compartments 15 separated by a membrane having a nominal cut off size of 30 kD. The device was spun at 2000 rpm for 2 hours at +4°C. The filtrate that had collected in the inner compartment was removed by pipetting and the centrifugation continued for a further 2 hours. This procedure was repeated a further two times after which the inner compartment with the membrane was replaced. The series of centrifugations was 20 then repeated. By this means, 20 ml of filtrate, the nominal 0-30 kD fraction, was obtained from the plasma fraction. The nominal 0-30 kD fraction was stored in a plastic bottle at -10°C or used in 3 below.

3. Preparation of the nominal 10-30 kD molecular weight sub-fraction from sheep ovarian plasma

25 The nominal 0-30 kD plasma fraction, from 2 above, was poured into an Amicon Centriprep-10, having a nominal cut off size of 10 kD. The device was spun at 2000 rpm for one hour at +4°C. The filtrate that had collected in the inner compartment was removed by pipetting and the procedure was repeated until approximately 2 ml of sample remained in the outer compartment. This was diluted 30 to 15 ml with phosphate-buffered saline (PBS) and the centrifugation repeated until the volume in the outer compartment was reduced to approximately 2 ml. The resultant fraction, the nominal 10-30 kD sub-fraction, was stored in a plastic bottle at -10°C or used in 4 below.

4. Preparation of the nominal 10-20 kD molecular weight sub-fraction from sheep ovarian plasma

The nominal 10-30 kD plasma sub-fraction, from 3 above, was then concentrated to 800 μ l with an Amicon Centricon-10, a small centrifuge device fitted with a membrane having a nominal cut off of 10 kD, by spinning in a centrifuge at 2000 rpm for one hour. 200 μ l aliquots were then applied to an FPLC gel filtration column (Pharmacia Superdex-75, HR 10/30, 30 cm long, 1 cm diameter) that had been calibrated with protein molecular weight standard. Elution was carried out with 25 ml PBS over a period of 25 minutes and 0.5 ml fractions were collected. Fractions falling within the nominal 10-20 kD molecular weight range were pooled, to give the nominal 10-20 kD sub-fraction, and stored in a plastic bottle at -10°C or used in 5 below.

5. Preparation of the three ion-exchange (sodium chloride) fractions from the nominal 10-20 kD sub-fraction of sheep ovarian plasma

The nominal 10-20 kD molecular weight sub-fraction of sheep ovarian plasma, from 4 above, was concentrated by centrifugation in an Amicon Centricon-3 (5 ml down to 1 ml). The concentrated fraction was subjected to buffer exchange with 20 mM Tris.HCl buffer, pH 7, by repeated dilution and reconcentration in an Amicon Centriprep-3 and Centricon-3. 500 μ l aliquots were then applied to a FPLC ion exchange column (Pharmacia Mono-Q, HR 5/5, 4 cm long, 0.5 cm diameter) and eluted with a linear gradient of 0-0.3 M sodium chloride solution in 20 mM Tris.HCl buffer, pH 7. The elution ran for 15 minutes at a flow rate of 1 ml/minute and 0.5 ml fractions were collected. The eluate fractions were divided into three pools corresponding to 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M sections of the NaCl gradient.

25 Example 1A

In order to improve yields, certain procedures recited in Example 1 may be changed, as follows:

2. Preparation of the nominal 0-30 kD molecular weight fraction from sheep ovarian plasma

The plasma was cleared by centrifugation at 2000 g, or equivalent for 10 minutes. The cleared plasma (120 ml) was then dispensed into 8 x Amicon Centriprep-30 filtration units and centrifuged at 1800 rpm for 10-12 hours at +4°C. The filtrate was harvested at intervals and centrifugation continued until a final volume of

80 ml was obtained. This nominal 0-30 kD fraction was stored overnight in polypropylene tubes at -20°C.

3. Preparation of the nominal 3-30 kD molecular weight fraction from sheep ovarian plasma

5 The nominal 0-30 kD molecular weight fraction (generated as detailed in 2. above) was dispensed into 6 x Amicon Centriprep-3 filtration units and centrifuged at 1800 rpm for 8-10 hours at +4°C. Centrifugation was performed until 2 ml of retentate remained in the outer compartment of each Centriprep-3 unit. The retentate (3-30 kD molecular weight sub fraction) was stored overnight at -20°C. The retentate was
10 subsequently, concentrated to a final volume of 500 µl in an Amicon Centricon-3 unit. After centrifuging the samples at 3000 rpm for 1-2 hours at + 4°C, the retentate was placed on ice before applying to the gel filtration column as detailed in 4. below.

4. Preparation of the nominal 10-20 kD molecular weight sub fraction from sheep ovarian plasma

15 Samples (2 x 200 µl) prepared in 3. above were subsequently applied to an FPLC gel filtration column (Pharmacia Superdex-75, HR 10/30, 30 cm long, 1 cm diameter) that had been calibrated with protein molecular weight standards. Elution was effected in PBS and fractions (1 ml/tube) were collected over a period of 45 minutes. Fractions falling within the nominal 10-20 kD molecular weight range were
20 pooled and concentrated to 2 ml by centrifugation in a Centriprep-3 unit (1800 rpm for 1-2 hours at + 4°C). The retentate was either stored in polypropylene tubes at -20°C or used in 5. below.

5. Preparation of ion exchange (sodium chloride) fractions from the nominal 10-20 kD molecular weight sub fraction of sheep ovarian plasma

25 The concentrated fraction generated in 4. above was subjected to buffer exchange by dilution to 15 ml in 20 mM Tris.HCl buffer, pH 7.6. The Centriprep-3 unit was centrifuged as before for (1800 rpm at +4°C) 6-8 hours. This fraction was further concentrated to ~500 µl in Centricon-3 units (3000 rpm for 1-2 hours at +4°C). Samples (2 x 200 µl) were then applied to a Vydac's Protein SAX HPLC ion exchange
30 column (0.75 x 5 cm) and eluted with a linear gradient of 0-1 M sodium chloride in 20 mM Tris.HCl buffer, pH 7.6. Eluted fractions (2 ml/tube) were collected over 45 minutes and activity tested in the rat bioassay (Example 3).

Example 2 Pharmaceutical Composition

Sterile-filtered micrin (5.5 ml; specific activity 1 unit/ml, as described herein) as the 0.1-0.2 M NaCl active ion exchange fraction as described herein and suitably diluted with physiological, pyrogen-free saline, and supplied in a sterile glass vial. The dose (5 ml) can be administered by injection into the peritoneum using a sterile needle.

Example 3 Bioassay

Whole plasma and the various fractions of partially purified micrin from Example 1 above were tested by *in vivo* bioassay as described below:

Adult female Wistar albino rats (weight 200-220 g) or adult male Wistar albino rats (weight 300-400 g) were injected intraperitoneally using sterile needles, 0.5 x 16 mm, 25 g, with daily 1 x 1 ml doses of the sheep ovarian venous plasma (or one of the other fractions prepared in Example 1 above) for four days. Ninety-six hours after the commencement of dosing, the rats were then anaesthetised (terminally using carbon dioxide) and the thorax opened surgically. The rats were then partially exsanguinated by cardiac puncture (5 ml); and then each of the rats underwent whole body dissection as described by Hart, Toxicology (1990) 61:185-194.

The following organs were removed from the partially exsanguinated female rats in a standard order, trimmed free of connective tissue and fat, and weighed: heart, liver, pituitary gland, adrenal glands, kidneys, spleen, uterus and ovaries; from male rats: heart, liver, pituitary gland, adrenal glands, kidneys, spleen, prostate and testes. Each of the organs was weighed and the results expressed as a percentage of the whole rat terminal body weight (g/kg or %).

Control experiments were carried out using the same procedure with sheep jugular whole venous plasma and similar fractions (molecular weight or ion exchange fractions) derived from sheep jugular venous plasma obtained as above in Example 1, but from ovariectomised sheep, clomiphene-untreated.

The results of reduction in organ mass obtained using the active plasma, fractions of active plasma, sub-fractions of active plasma and ion exchange fractions of active plasma are given in Figures 1 to 5.

CLAIMS

1. A material having the ability to reduce organ mass, the material being obtainable by:

5 collecting ovarian venous blood from a female mammal;

preparing ovarian venous plasma from the blood; and

at least partially purifying said material from the plasma.

2. A material according to claim 1, wherein the purifying comprises obtaining the 10-30 kD fraction.

3. A material according to claim 1, wherein the purifying comprises obtaining the 10 10-20 kD fraction.

4. A material according to claim 3, wherein the purifying additionally comprises ion exchange chromatography, and collecting the fraction eluted in 0.1-0.2 M NaCl.

5. A material according to claim 1, wherein the purifying comprises the following protocol:

15 plasma cleared by centrifugation;

cleared plasma spun to give a nominal 0-30 kD fraction;

nominal 0-30 kD fraction spun to give a nominal 10-30 kD sub-fraction;

nominal 10-30 kD sub-fraction concentrated and gel-filtered to give a nominal 10-20 kD sub-fraction;

20 nominal 10-20 kD sub-fraction repeatedly concentrated and buffer-diluted, applied to an ion exchange column eluted with a gradient of 0-0.3 M NaCl; and

eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.



25 6. A material according to any preceding claim, wherein the mammal is a sheep.

7. A material according to any preceding claim, for therapeutic use.

8. A pharmaceutical composition comprising a material according to any of claims 1 to 6 and a pharmaceutically acceptable excipient or carrier.

30 9. Use of a material according to any of claims 1 to 6, for the manufacture of a medicament for the treatment of organ or tissue hypertrophy.

Fig.1.
Fig.2.



2/3

Fig.4.




Fig.3.





Fig.5.



DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of subject matter which is claimed and for which a patent is sought on an invention entitled
ISOLATED MATERIAL HAVING AN ANTI-ORGANOTROPHIC EFFECT

the specification of which is attached hereto or

was filed on 01 DEC 1999 as United States Application Number or PCT International Application Number PCT/GB99/04013 and was amended on (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for a patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application Number(s)	Country	Foreign Filing Date	Priority Not Claimed	Certified Copy Attached?	
			YES	NO	
9826186.0	GB	01 DEC 1998	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: David R. Saliwanchik, Reg. 31,794; Jeff Lloyd, Reg. 35,589; Doran R. Pace, Reg. 38,261; Christine Q. McLeod, Reg. 36,213; Jay M. Sanders, Reg. 39,355; James S. Parker, Reg. 40,119 and Jean E. Kyle, Reg. 36,987; Frank C. Eisenschenk, Reg. 45,332; Seth M. Blum, Reg. 45,489

Direct all correspondence to:

Saliwanchik, Lloyd & Saliwanchik
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669
 USA

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C 1001 and that such willful false statements may jeopardise the validity of the application or any patent issued thereon.

Full name of sole or
First Inventor

John Ernest HART

Inventor's signature

John Hart

Residence address

Hants
Herts, United Kingdom

Post Office address

John Hart Wilderness End, Tadley Common Road, Tadley, Hampshire
~~19 Herbert Street, Old Town, Hemel Hempstead, Herts~~ RG26 3TA,
~~HP2 5HP, United Kingdom~~ John Hart United
Kingdom

Country of Citizenship United Kingdom

Date of signature 31st May 2001